1. Home
  2. CXH vs IFRX Comparison

CXH vs IFRX Comparison

Compare CXH & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Investment Grade Municipal Trust

CXH

MFS Investment Grade Municipal Trust

HOLD

Current Price

$7.95

Market Cap

65.0M

Sector

Finance

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.18

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXH
IFRX
Founded
1989
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.0M
71.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CXH
IFRX
Price
$7.95
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
25.9K
650.6K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
3.56%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
N/A
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
$33.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.41
$0.71
52 Week High
$7.74
$2.77

Technical Indicators

Market Signals
Indicator
CXH
IFRX
Relative Strength Index (RSI) 53.90 55.81
Support Level $7.87 $0.99
Resistance Level $8.01 $1.16
Average True Range (ATR) 0.08 0.08
MACD 0.00 0.02
Stochastic Oscillator 75.00 97.37

Price Performance

Historical Comparison
CXH
IFRX

About CXH MFS Investment Grade Municipal Trust

Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: